← FDA DRUG APPROVALS

FDA ANDA · ANDA075161

TICLOPIDINE HYDROCHLORIDE

Sponsor: MYLAN

APPLICATION
ANDA075161
TYPE
ANDA
ORIGINAL APPROVAL
1999-09-13
LATEST ACTION
2002-10-29
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

TICLOPIDINE HYDROCHLORIDEDiscontinued
TICLOPIDINE HYDROCHLORIDE 250MG · TABLET · ORAL

Approval history

2002-10-29Labeling · Supplement 5AP
2002-03-13Labeling · Supplement 4AP
2001-05-30Manufacturing (CMC) · Supplement 3AP
2001-01-03Labeling · Supplement 2AP
2000-11-06Manufacturing (CMC) · Supplement 1AP
1999-09-13OriginalLabelAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →